188
Participants
Start Date
August 22, 2019
Primary Completion Date
October 6, 2021
Study Completion Date
October 6, 2021
Dupilumab
Pharmaceutical form: solution for injection Route of administration: subcutaneous
Placebo
Pharmaceutical form: solution for injection Route of administration: subcutaneous
Investigational Site Number :3800002, Roma
Investigational Site Number :0360001, Kogarah
Investigational Site Number :0360006, Phillip
Investigational Site Number :7560001, Bern
Investigational Site Number :0360003, Carlton
Investigational Site Number :0360007, Woolloongabba
Investigational Site Number :7240006, Córdoba
Investigational Site Number :7240004, Granada
Investigational Site Number :3760005, Afula
Investigational Site Number :3800005, Rozzano
Investigational Site Number :7240008, Madrid
Investigational Site Number :7240010, Madrid
Investigational Site Number :2500001, Brest
Investigational Site Number :8400008, Charleston
Investigational Site Number :2500006, Toulouse
Investigational Site Number :8400003, Sarasota
Investigational Site Number :2760001, Göttingen
Investigational Site Number :7240005, Seville
Investigational Site Number :2500003, Nantes
Investigational Site Number :7240002, Valencia
Investigational Site Number :7840002, Abu Dhabi
Investigational Site Number :7240003, Manises
Investigational Site Number :2760004, Münster
Investigational Site Number :2760005, Bad Bentheim
Investigational Site Number :3800003, Siena
Investigational Site Number :3800001, Pisa
Investigational Site Number :2760002, Frankfurt am Main
Investigational Site Number :8400012, North Little Rock
Investigational Site Number :2500002, Paris
Investigational Site Number :8400005, Denver
Investigational Site Number :8400013, Colorado Springs
Investigational Site Number :3800004, Reggio Calabria
Investigational Site Number :2760006, Friedrichshafen
Investigational Site Number :8400001, Rolling Hills Estates
Investigational Site Number :3760003, Jerusalem
Investigational Site Number :8400002, Redwood City
Investigational Site Number :8400007, Medford
Investigational Site Number :3800006, Perugia
Investigational Site Number :7240001, Barcelona / Sabadell
Investigational Site Number :7840001, Dubai
Investigational Site Number :8260002, Dudley
Investigational Site Number :8260004, Edinburgh
Lead Sponsor
Regeneron Pharmaceuticals
INDUSTRY
Sanofi
INDUSTRY